Education
About Us
Working with TipRanks
Follow Us
Alpha Teknova (TKNO)
NASDAQ:TKNO
Top Page
Alpha Teknova
(NASDAQ:TKNO)
Select Model
Select Model
Rating:49Neutral
Price Target:
$2.00
▼(-11.11% Downside)
Action:ReiteratedDate:02/27/26
The score is held back primarily by persistent losses and negative free cash flow despite improving revenue and margins. Technical signals also remain weak with the stock below key moving averages and a negative MACD. Offsetting these risks, the latest earnings call showed continued operational progress and a clearer path toward improved margins and reduced cash outflow, though near-term guidance remains modest.
Positive Factors
Revenue Momentum
Sustained top-line growth across six consecutive quarters indicates improving product-market fit and traction. For a consumables business, recurring demand from lab and process workflows can compound growth, enabling capacity utilization gains and more predictable scaling toward break-even.
Improving Gross Margins
Material margin recovery driven by higher volumes and manufacturing efficiencies signals meaningful operating leverage. Sustained mid‑30s margins reduce cash burn per dollar of revenue and create headroom to fund commercial investment while progressing toward longer term margin targets.
Clinical Pipeline & Customer Growth
Expansion of clinical customers and therapy support builds a pipeline of high-value, recurring commercial opportunities. Success converting clinical programs to commercial supply would diversify revenue, raise average order sizes, and materially strengthen long-term revenue visibility.
Negative Factors
Persistent Cash Burn
Multi-year negative operating and free cash flow means the business still depends on external financing or cash reserves to operate. Even with improvement, ongoing outflows constrain reinvestment cadence and increase risk of dilution or funding shortfalls if market access tightens.
Sustained Net Losses
Continued material net losses erode equity and limit financial flexibility. Achieving scaled profitability requires sustained revenue growth plus continued margin expansion; failure to execute risks further capital raises, which could dilute shareholders and slow strategic initiatives.
Revenue Dependence & Lumpiness
Reliance on external biotech funding with a multi-quarter lag and large, timing-sensitive clinical orders creates structural volatility. That unpredictability complicates capacity planning, cash forecasting, and consistent margin improvement, slowing reliable progress to targets.
Alpha Teknova (TKNO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$118.43M
Dividend YieldN/A
Average Volume (3M)318.88K
Price to Earnings (P/E)―
Beta (1Y)1.10
Revenue Growth9.50%
EPS Growth53.74%
CountryUS
Employees173
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.09
Shares Outstanding53,587,660
10 Day Avg. Volume259,294
30 Day Avg. Volume318,881
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)2.96
Price to Sales (P/S)5.02
P/FCF Ratio-22.01
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue3.15
Enterprise Value/Gross Profit9.49
Enterprise Value/Ebitda-11.99
Forecast
1Y Price Target
$7.00Price Target Upside211.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$43.01M
Alpha Teknova Business Overview & Revenue Model
Company DescriptionAlpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
How the Company Makes MoneyAlpha Teknova generates revenue primarily through the sale of its custom reagents and molecular biology products, which are tailored to meet the specific needs of its customers. The company offers a wide range of products, including buffers, enzymes, and other laboratory supplies, which are sold both directly and through distribution partnerships. Key revenue streams include bulk orders from pharmaceutical companies and recurring sales to research institutions and laboratories. Additionally, Teknova may engage in collaborations or partnerships with larger biotech firms, enhancing its reach and providing opportunities for co-development projects, which can further contribute to its earnings.
Alpha Teknova Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Positive
The call portrayed clear operational and financial progress: revenue growth (6th straight quarter), improved gross margins, narrower net losses and adjusted EBITDA, better free cash flow performance, growing clinical customer count and pipeline progress. Management is beginning to reinvest (~$2M) in commercial capabilities, providing a plausible path to adjusted EBITDA positivity by end of 2027 (targeting $52M–$57M annualized revenue). Key near-term risks include ongoing negative adjusted EBITDA and free cash outflow, lowered average revenue per customer from new/early-stage accounts, revenue lumpiness in Clinical Solutions, and reliance on a sustained biotech funding recovery (with a ~4-quarter lag) to accelerate revenue. Overall, the company is trending in the right direction but still requires execution and favorable market conditions to meet longer-term targets.Q4-2025 Updates
Positive Updates
Revenue Growth and Momentum
Total revenue of $40.5M in FY2025, a 7% increase from $37.7M in FY2024; Q4 revenue $10.0M, up 8% YoY. This marks the company's sixth consecutive quarter of revenue growth.
Catalog and Lab Essentials Performance
Catalog products led growth (low double-digit growth vs 2024). Lab Essentials revenue was $31.0M in 2025, up 7% YoY; ~75% of Lab Essentials revenue came from catalog products.
Clinical Solutions Acceleration
Clinical Solutions revenue was $2.7M in Q4 2025, a 47% YoY increase, and $7.7M for FY2025, up 8% YoY. Clinical customers grew from 48 in 2024 to 60 in 2025 (25% increase).
Clinical Pipeline Traction
Supporting at least 70 therapies (up from prior year), including 5 in Phase II or later (up from 3) and 12 in Phase I (up from 10); management expects to support at least one commercial therapy by end of 2027.
Gross Margin and Profitability Improvement
Gross profit rose to $13.4M for FY2025 from $7.2M in FY2024. Gross margin improved to 33.2% for FY2025 from 19.2% in FY2024 (Q4 margin 32.5% vs 23.0% prior year); improvement driven by higher revenue and manufacturing efficiencies (adjusted for a $2.8M 2024 nonrecurring inventory charge).
Adjusted EBITDA and Net Loss Improvements
Adjusted EBITDA improved to negative $6.7M for FY2025 from negative $14.5M in FY2024 (Q4 adjusted EBITDA negative $1.8M vs negative $3.2M prior year). Net loss narrowed to $17.3M ($0.32/share) in FY2025 from $26.7M ($0.57/share) in FY2024.
Cash Flow and Balance Sheet Progress
Free cash outflow improved to negative $9.8M in FY2025 from negative $13.5M in FY2024, beating guidance of <$12M. Cash, cash equivalents and short-term investments totaled $21.3M at year-end with $13.2M gross debt.
Operational Metrics and Cost Discipline
Delivered ~95% of products on time in 2025; ~95% annual customer retention; over 3,000 customers; top 10 Lab Essentials customers represented only 18% of revenue. Headcount reduced to 158 from 173; operating expenses (ex nonrecurring) below $8M for seven consecutive quarters.
Forward-Looking Targets and Investment Plan
2026 revenue guidance of $42M–$44M (midpoint ≈ 6% growth). Company plans ~$2M incremental annual commercial investment in 2026 to accelerate growth; expects adjusted EBITDA positivity by end of 2027 at $52M–$57M annualized revenue and incremental revenue margin contribution of ~70% to the bottom line.
Negative Updates
Continued Negative Adjusted EBITDA and Cash Burn
Adjusted EBITDA remained negative $6.7M for FY2025 and free cash flow was negative $9.8M, indicating ongoing cash burn despite improvements; management forecasts continued negative free cash outflow (< $10M) in 2026 due to new commercial spend.
Net Losses Persist
Net loss of $17.3M ($0.32/share) for FY2025, improving from $26.7M in FY2024 but still a material operating loss with multi-year path required to reach sustained profitability.
Decline in Average Revenue per Customer
Average revenue per customer decreased: Lab Essentials average revenue per customer fell ~3% for the year, and Clinical Solutions average revenue per customer decreased 14% in 2025 to $128,000, partly due to addition of newer, lower-spend customers.
Dependence on Biotech Funding Recovery
Revenue recovery in biopharma is tied to external biotech funding with an estimated ~4-quarter lag; management did not bake a biotech funding recovery into 2026 guidance and is awaiting sustained funding trends, creating revenue timing risk.
Lumpiness and Order Concentration Risk in Clinical Solutions
Clinical Solutions revenue can be lumpy due to larger average order sizes and timing of larger clinical customers; management noted lack of material increase in larger Clinical Solutions orders for 2026 currently.
Modest Near-Term Guidance
2026 guidance midpoint implies ~6% revenue growth—modest relative to the company’s long-term target of 20%–25% annual growth—leaving a gap that must be closed by market recovery, commercial investments, or M&A.
Prior Inventory Charge Distorted Comparables
A $2.8M nonrecurring, noncash inventory charge in 2024 complicated year-over-year comparisons and inflated apparent margin improvement when not adjusted.
Company Guidance
Teknova guided 2026 revenue of $42.0–$44.0 million (midpoint ≈6% growth vs $40.5M in 2025), expects gross margin in the mid‑30s (vs 33.2% in 2025), and will increase sales & marketing spend by about $2.0 million while targeting free cash flow outflow of less than $10.0 million (2025 FCF outflow was $9.8M, below prior <$12M guidance). Management reiterated that each incremental dollar of revenue drops to the bottom line at roughly a 70% marginal cash rate (with some quarter‑to‑quarter GAAP variability) and said it is targeting adjusted EBITDA positivity by the end of 2027 once annualized revenue reaches roughly $52–$57M (about $13–$14M per quarter); longer‑term aspirations include 60–65% gross margins and 25–30% adjusted EBITDA margins. They also noted a ~4‑quarter lag between biotech funding and revenue, so sustained increases in funding could drive biopharma revenue growth beginning in Q4 2026 and create upside to 2026 guidance.Alpha Teknova Financial Statement Overview
Summary
Strong 2025 revenue rebound and improved gross margin, plus reduced leverage, but the business remains meaningfully unprofitable and continues to burn cash (negative operating and free cash flow across 2021–2025). Overall profile still looks like an early-stage turnaround.Income Statement
Revenue rebounded strongly in 2025 (up ~181% vs. 2024) after several uneven years, and gross margin improved to ~33% from ~19% in 2024. However, profitability remains weak: the company is still operating at meaningful losses (2025 net margin ~-43%), and it has been loss-making for five straight years after a profitable 2020. The trend is improving versus 2022–2024, but the business has not yet demonstrated sustainable earnings power.32
Negative
Balance Sheet
Leverage looks manageable and improving, with total debt down sharply in 2025 and debt-to-equity declining to ~0.22 (from ~0.37 in 2024). Equity remains sizable relative to debt, which provides some balance-sheet flexibility. The key weakness is ongoing losses, which have coincided with a multi-year decline in equity and create continued pressure on the capital base if profitability does not turn.58
Neutral
Cash Flow
Cash generation is a clear weak spot: operating cash flow and free cash flow are negative across 2021–2025, indicating the company is consuming cash rather than funding itself internally. While cash burn improved versus the heavier outflows seen in 2022–2023, free cash flow worsened in 2025 versus 2024, and the business still relies on balance-sheet resources and/or financing to sustain operations.27
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 40.52M | 37.74M | 36.68M | 41.42M | 36.89M |
| Gross Profit | 13.44M | 7.23M | 10.30M | 17.48M | 17.62M |
| EBITDA | -10.15M | -19.57M | -25.54M | -25.69M | -9.13M |
| Net Income | -17.26M | -26.75M | -36.78M | -47.47M | -9.80M |
Balance Sheet | |||||
| Total Assets | 103.58M | 118.77M | 128.59M | 152.26M | 166.51M |
| Cash, Cash Equivalents and Short-Term Investments | 5.91M | 30.40M | 28.48M | 42.24M | 87.52M |
| Total Debt | 15.15M | 30.17M | 30.46M | 42.31M | 11.87M |
| Total Liabilities | 34.81M | 36.38M | 38.55M | 52.38M | 23.31M |
| Stockholders Equity | 68.78M | 82.39M | 90.04M | 99.89M | 143.20M |
Cash Flow | |||||
| Free Cash Flow | -9.23M | -13.52M | -26.75M | -55.55M | -28.95M |
| Operating Cash Flow | -8.08M | -12.39M | -18.81M | -27.40M | -9.07M |
| Investing Cash Flow | 10.70M | -27.27M | -7.74M | -28.15M | -17.52M |
| Financing Cash Flow | 151.00K | 14.89M | 12.80M | 10.27M | 110.79M |
Alpha Teknova Technical Analysis
Negative
2.25
Price Trends
3.01
Negative
3.94
Negative
4.51
Negative
Market Momentum
-0.18
Negative
38.35
Neutral
52.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TKNO, the sentiment is Negative. The current price of 2.25 is above the 20-day moving average (MA) of 2.20, below the 50-day MA of 3.01, and below the 200-day MA of 4.51, indicating a neutral trend. The MACD of -0.18 indicates Negative momentum. The RSI at 38.35 is Neutral, neither overbought nor oversold. The STOCH value of 52.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TKNO.
Alpha Teknova Risk Analysis
Alpha Teknova disclosed 71 risk factors in its most recent earnings report. Alpha Teknova reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Alpha Teknova Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $850.92M | -2.61 | -25.64% | ― | ― | -1.89% | |
57 Neutral | $261.06M | -19.19 | -47.05% | ― | 2.82% | 60.26% | |
55 Neutral | $590.27M | -60.05 | ― | ― | -10.42% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $118.43M | -11.78 | -22.79% | ― | 9.50% | 53.74% | |
45 Neutral | $263.01M | -6.89 | ― | ― | 0.47% | -430.88% |
* Healthcare Sector Average
TKNO
Alpha Teknova
2.21
-3.88
-63.71%
IRWD
Ironwood Pharma
3.62
2.12
141.33%
LFCR
Lifecore Biomedical
7.02
0.84
13.59%
SXTC
China SXT Pharmaceuticals
2.04
-644.90
-99.68%
DERM
Journey Medical Corp
7.85
2.71
52.72%
BIOA
BioAge Labs, Inc.
20.38
15.83
347.91%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.